Sakshi. B. Chaudhari, Harsha. S. Suryawanshi, Azam Z. Shaikh, S. P. Pawar, Ritik. S. Jain
Sakshi. B. Chaudhari, Harsha. S. Suryawanshi, Azam Z. Shaikh, S. P. Pawar, Ritik. S. Jain
Department of Pharmacology, P.S.G.V.P. M’s College of Pharmacy, Shahada.
Department of Pharmacology, Ahinsa Institute of Pharmacy, Dondaicha.
Volume - 14,
Issue - 3,
Year - 2022
The world stands for Acquired immunodeficiency syndrome. The public understanding of AIDS as a highly critical acute illness with a rapid downward trajectory was crystallized nevertheless. In that some of advanced stages of that disease. Many countries has allowed AIDS to reach catastrophic level. AIDS is effect on mental state of injected person. The person may undergo depression. The mental health could be improved by acquisition of social support like friends and family. Provide helpful links like education, health care and social support. AIDS is sexually transmitted disease. It can be spread through person to person. AIDS is responsible for behaviour changes. Research has worked hard to compreshed the AIDS epidemic since its inception nature of the disease and its manifestation. The human immunodeficiency virus (HIV) is the causative agent (HIV). The two of them HIV-1 and HIV-2 are the most common type of HIV. The three diploid single stranded RNA genomes protease, reverse transcriptase, and viral enzyme integrates. AIDS does not have a cure. The greatest choice is prevention. Infection in blood transfusion patients of course, is a new-born (from mother). It is a malady that can only be tackled, by the social and mental fraternity acting together, to prevent the spread of the disease. There are significant continuities as well as discontinuities in the experience of living with HIV/AIDS during the last two decided, as this reveals release. The aids are sexually transmitted disease.
Cite this article:
Sakshi. B. Chaudhari, Harsha. S. Suryawanshi, Azam Z. Shaikh, S. P. Pawar, Ritik. S. Jain. AIDS: The Long term disease. Research Journal of Pharmacology and Pharmacodynamics.2022;14(3):155-8. doi: 10.52711/2321-5836.2022.00026
Sakshi. B. Chaudhari, Harsha. S. Suryawanshi, Azam Z. Shaikh, S. P. Pawar, Ritik. S. Jain. AIDS: The Long term disease. Research Journal of Pharmacology and Pharmacodynamics.2022;14(3):155-8. doi: 10.52711/2321-5836.2022.00026 Available on: https://rjppd.org/AbstractView.aspx?PID=2022-14-3-4
1. Siegel K, krauss B. Living with HIV infection: adaptive task of seropositive gay men. J Health SocBehav 1991, 32: 17-22.
2. Nokes k. Applying the chronic illeness trajectory model to HIV/AIDS. Such InqNuts pract 1991, 5: 197-204.
3. Jeu S. Psychosocial issues of AIDS long term survivors. Families Soc 1994, 75: 324-334.
4. Kobayashi, JS. The evolution of adjustment issue in HIV/AIDS. Bull menningerclin 1997, 61 (2.): 146-38.
5. Rabkin JG, ferrando S. A second life agenda: Psychiatric research issue raised by protease inhibitors treatment for people with the human deficiency virus or acquired immunodeficiency syndrom. Arch Gen psychiatry 1997, 54: 1049-1053.
6. Sowell RL, Philips KD, Grier J. Restructuring life to face the future: the perspective of men after a positive response to protease inhibitor therepy. AIDS patients care STDS 1998, 12: 33-42.
7. Centers for Disease control and prevention. update: trends in AIDS incidence- united state, 1996 Morbid Mortal WKly Rep 1997, 46: 861-867.
8. UNAIDS, WHO. Under Embargo. AIDS Epidemic update joint united Nation, programme on HIV/ AIDS (UNAIDS) and world health organisation (WHO). Geneva: December 2001.
9. Bassetti s, Battegay M, further H. et al. Why is highly active anti-retroviral therapy (HAART) not prescribed or discontinued? SWISS HIV cohort study. J acquire immune Deficsyndr 1999, 21: 114-119.
10. Maisels L, Steinberg J. Tobaisc. An investigation of why eligible patients do not receive HAART AIDS patient care 2001, 15: 185-191.
11. Herbert, B, Brownstone A, clanon K, Abercrombie P, Bangberg D. Combination anti-retroviral therapy: health care providers confront emerging dilemmas. AIDS care 2000, 12: 409-421.
12. Chesney MA, ICKOVICS J, Hecht FM, Sikia G, Rankin J. Adherence: a necessity for successful HIV combination therapy. AIDS 1999, 13 (SUPPLA): s271-s278.
13. Fogarty L, Roter D, Larson S, Burkaj, Gillespie J, levy R. Patients adherence to HIV medication regimens: a review of published and abstract reports. Patient Edvc coins 2002, 46: 93-108.
14. Cook JA, Cohen MH, Grey D, et al. Use of highly active anti-retroviral therapy in a cohort of HIV seropositive Women. Am J public Health 2002, 92: 82-87.
15. Jacobson LP, Gore ME, strathdee SA, phair JP, Riddler's, Detels R. Therapy naivete in the era of potent anti-retroviral therapy. J club Epidemial 2001, 54: 149-156.
16. Jeffe DB, Meredith KL, Mindy LM, Fraser VJ. Factors associated with HIV infected patients recognition and use of HIV medication. J acquir immune Deficsyndr Hum Retrovir 1998, 19: 359-360.
17. Mocroft A, Gill MJ, Davidson W, Philips AN. Are there gender differences in starting protease inhibitors, HAART and disease progression despite equal access to care? J Acquir immune Deficsyndr 2000, 24: 475-482.
18. Atklnson, J. H and Grant, I.(1994). Natural history of neuropsychiatric manifestation HIV disease. Psychiatric clinics of North America 17, 17-23.
19. HART, J, Einav, C, Weingarten, M.A and Stein, M (1990). the important of family support in a behaviour modification weight loss program. Journal of America Dietic association, 90, 1270-1271.
20. Sturat, R.B and DAVIS, B. (1972). slim chance in a fat world. Chicago, IL: Research press.
21. Wilcox, D.R.C., GILLAN, R and HARE, E.H (1965). do Psychiatric outpatient take their drugs? British Medical Journal,22, 790-792.
22. Nokes K. Revisiting how the chronic illness Framework can be applied to people living with HIV/ AIDS.schlnq Nuts pract 1998, 12: 27-31.
23. Bogart LM, Catz SL, Kelly JA. et al. Psychosocial issue in the era of new AIDS treatment from the perspective of person living with HIV.J Health psychol 2000, 5: 500-516.
24. Schultz MA Sanfort TG. HIV- positive people, risk and sexual behaviour. socsci Med 2000,50: 157-1588.
25. Barre- Sinoussi F. ChermannJc, Rey F, et al. Isolation of a T- lymphotropicretrovirus from patients risk for Acquir immune deficiency syndromes. Science (1983) 220: 863-70.
26. Popovic M, Sarngadhan MG, Read E, Gallo Rc, Detection isolation and continuous production of cytopathic retrovirus (HTLV-III) from patient with AIDS and pre AIDS Science 1984; 224: 500-04.
27. Hayami M, Ido E, minurat T, survey of simian immunodeficiency virus among non- human prvote population. Cure Top Microbial Immunol 1994; 188: 1-20.
28. Myers G. Maclnnes K, Korber B. The emergence of simian/ human immunodeficiency viruses. AIDS Res Hum Retrovir 1992; 8: 373-85.
29. Bukrinsky MI, Haggerty S, Dempsey MP, et al. A nuclear localisation signal within HIV-1 matrix protein that governs infection of non - dividing cells. Nature 1993; 365: 666-68.
30. Weiss RA. Cellular receptor and viral glycoprotein involved in retrovirus entry. In :LevyJA, ed. The Retrovirifae, vol3.New York plenum, 1993; 1-108.
31. Coffin JM. Structure and classification of retrovirus. I n: levy JA, ed the retroviridaevol 1. New York Plenum, 1992: 29-50.
32. Levy JA. Pathogenesis of human immunodeficiency virus Infections Microbial Rev 1993; 57: 183-289.
33. Strebel K, Davgherty D, clause K, Cohen D, folks T, Martin MA . The HIV a (SOR) gene product is essential for virus infectivity. Nature 1987; 328: 728-30.
34. Strebel K, Kimkait T, Martin MA. A novel gene of HIV-1, Vpu and it's 16- kilodalton product. Science 1988; 241; 1221-23.
35. Bukrinsky MI., Sharova N, Derpsey MP. active nuclear import of human, immunodeficiency virus type 1 proteingration complexes pro Nal-1 Acadsci USA 1992; 89: 6580-84.
36. Benn S, Ruttedge R, Folks T, et al genomic heterogeneity of AIDS retroviral isolates from north America and Zaire science 1985; 230: 949-57.
37. Goodenow M, Hurt T, Saurin W, Kwoks, Sninsky J, wain- Hobson S HIV-I isolates are rapidly evolving quasispecies; evidence for viral mixture and preferred nucleotide substitution. J acquire immune Deficsyndr 1989; 2; 344-52.
38. Cannot RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Viral 1994; 64: 4400-08.
39. Wei X. Gosh SK, Taylor ME, et al viral dynamic in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
40. Ho DD, Neumann AV, perelson As, et al Rapid turnover of plasma variation and CD4 lymphocytes in HIV-l infection. Nature 1995; 373: 123-26.
41. Caffin J. Genetic diversity and evolution of retroviuses. Cure topic Microbial Immunol 1992; 176; 143-64.
42. Chesney MA. factors affecting adherence to anti-retroviral therapy. CL n Infect Dis 2000, 30(suppl2): s 171-s 176.
43. D' ArminioMonteforte A, lepri AC, Rezza G, et al. Insight into the reason of discontinuation therapy (HAART) regimen in a cohort of anti-retroviral naive patients I.CO.N.A. studygroup. italian cohort of anti-retroviral naive patients. AIDS 2000,14: 499-507.
44. Gold RS, Hinchy J, Batrouney CG. The reasoning behind decision not to take up anti-retroviral therapy in Australian infected with HIV. Int STD AIDS 2000,11: 361-370.
45. Izopet J, Massip P, Sourish, et al. Shift in HIV resistance and short term antiviral effect following a new salvage regimen. AIDS 2000, 14: 2247-2255.
46. Maggiolo, F, Callengaro A, Gregis G, et al. Strategic selective treatment in highly pre- treated HIV patients harbouring multiply resistant virus. AIDS 2002, 16: 289-299.
47. kelly JA, otto - Salaj LL, sikkema KJ, pinkerton SD, Bloom FR. Implications OF HIV treatment advances For behavioral research on AIDS protease inhibitors and the new challenges. in HIV primary prevention. Health Psycho" 1998, 17: 310 319.
48. Selwyn P, Arnold R. from fate to tragedy: the changing meanings of life death and AIDS, Ann Intern Med 1998, 129: 899-902.
49. Mind, C. and white D. O (1984) viral pathogenesis and Immunology (Blackwell, Oxford).
50. Fvans A.S. (1989) J. Acquired Immune Deficiency -syndr 2, 107 -113.
51. Duesberg, P.H. (1989) J. Acquired Immune Deficsyndr 2, 514-517.